tradingkey.logo
tradingkey.logo

Kura falls after downbeat fourth-quarter results

ReutersMar 5, 2026 1:35 PM

Shares of drugmaker Kura Oncology KURA.O fall 5.80% to $8.05 premarket

Co posts Q4 loss of 92 cents per share, while analysts were expecting a loss of 61 cents per share, according to data compiled by LSEG

Posts Q4 revenue of $17.3 million, below analysts' estimate of $53.6 million

R&D expenses for the quarter were $64.4 million, tied to advancement of combination trials for its blood cancer drug, ziftomenib - KURA

KURA shares had risen over 19% in 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI